Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease/dementia.

Patients treated with at least 12.5 mg/day of oral prednisone for at least 3 months had an 88% reduction in the risk of relapse compared with those who did not receive this regimen.

The therapy is the first and only neonatal Fc receptor blocker approved for the treatment of CIDP, and will be available as a once-weekly, 30- to 90-second subcutaneous injection.

Eric Herzog, PhD, a chronobiologist and professor of biology and neuroscience at Washington University, provided thoughts on a number of topics related to sleep during pregnancy and the significance of maintaining circadian rhythms.

A statistically significant dose-response correlation was observed, indicating that greater lifestyle changes led to better cognitive and functional outcomes in Alzheimer's patients.

CNM-Au8, an oral suspension of clean-surfaced, catalytically-active gold nanocrystals, resulted in prolonged survival and reductions in neurofilament light, a prominent biomarker of neuroaxonal damage.

ND0612, an investigational agent, had supportive data from the pivotal phase 3 BouNDless trial, a large-scale, phase 3 study of patients with Parkinson disease.

The director at the Foundation for the National Institutes of Health provided commentary on a recently launched partnership aimed at building a repository of ALS data to advance drug development for the disease.

Initial data from a few pediatric and adult patients with Rett syndrome showed that treatment with TSHA-102 resulted in numerous positive enhancements across multiple efficacy measures and clinical domains.

Patients with Parkinson disease and depression exhibit significantly worse nonmotor symptoms, highlighting the need for comprehensive management including orthostatic hypotension, constipation, and hyposexuality.

Douglas A. Wadja, PhD, an assistant professor of neurology at Cleveland State University, detailed a study assessing an electrical nerve stimulation approach to alleviate gait dysfunction in patients with MS.

Across both the primary and secondary end points, treatment with TAK-861 resulted in significant improvements in symptom severity among patients with narcolepsy type 1.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on narcolepsy.

Ron Grunstein, MD, PhD, head of Sleep and Circadian Research at the Woolcock Institute of Medical Research, provided commentary on early, promising data regarding investigational agent ALKS 2680 in patients with narcolepsy type 1.

Rakesh Jain, PhD, MS, clinical professor of psychiatry at the Texas Tech University School of Medicine, provided insight on a recently approved tablet dosage for deutetrabenazine, an FDA-approved therapy for chorea and tardive dyskinesia associated with Huntington disease.

AOC 1020 (del-brax) from Avidity Biosciences shows over 50% reduction in DUX4 regulated genes, trends of functional improvement, and favorable safety in FSHD patients.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Anthony Feinstein, PhD, FRCPC, MBBCh; Brian G. Weinshenker, MD; Douglas A. Wajda, PhD; Le Hua, MD; and Eoin P. Flanagan, MB, BCh. [LISTEN TIME: 22 minutes]

For up to 24 months, patients on mirdametinib demonstrated significant improvements in pain severity, pain interference, and health-related quality of life, in addition to deep and durable plexiform neurofibroma volume reductions.

Although a small sample of 5 patients with DMD, results showed significant expression of microdystrophin and reductions in creatine kinase, a biomarker of muscular distress, in GTN0004-treated patients.

Deflazacort, a corticosteroid approved for children with Duchenne muscular dystrophy, has been on the market since 2017 under the name Emflaza.

John Novak, MD, MS, director of the OhioHealth ALS Clinic and vice chair of the ALS Association Care Services Committee, provided insight on the upcoming ALS Nexus Conference, the first ever educational event from the organization, spanning multiple days in July.

The FIREFISH study showed that most children maintained or improved motor functions and feeding abilities over five years.

In a pivotal, large-scale, phase 3 trial, donanemab met its primary end point, demonstrating more pronounced effects in patients with early-stage Alzheimer disease who had low/medium tau status.

The Minority Stroke Program, open since 2019, encompasses a group of highly trained stroke experts who provide high quality care and education for minority ethnic patients presenting with stroke.

If the sBLA is approved, the clinical and biomarker benefits may be maintained through the once-monthly dosing regimen that is less burdensome and easier for patients and care partners to continue long-term.

After 28 days of treatment, bezisterim showed pronounced effects on measures of the Non-Motor Symptom Scale, as well as greater achievement of ON time than levodopa alone.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke and large hemispheric infarction.

In a subgroup of patients who underwent endovascular thrombectomy in addition to IV glibenclamide, results showed improved functional outcomes favoring active treatment, coupled with greater reductions in mortality.

Biogen's tofersen, an antisense oligonucleotide, remains the first and only marketed therapy to treat patients with SOD1-mutated amyotrophic lateral sclerosis.

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.